-
1
-
-
34250011735
-
Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients
-
DOI 10.1517/13543784.16.6.777
-
Hadziyannis SJ. Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients. Expert Opin Investig Drugs 2007;16:777-786. (Pubitemid 46882353)
-
(2007)
Expert Opinion on Investigational Drugs
, vol.16
, Issue.6
, pp. 777-786
-
-
Hadziyannis, S.J.1
-
2
-
-
66149115173
-
Longterm monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy
-
Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Longterm monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-1514.
-
(2009)
Hepatology
, vol.49
, pp. 1503-1514
-
-
Tenney, D.J.1
Rose, R.E.2
Baldick, C.J.3
Pokornowski, K.A.4
Eggers, B.J.5
Fang, J.6
-
3
-
-
78650477355
-
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B
-
Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140:132-143.
-
(2011)
Gastroenterology
, vol.140
, pp. 132-143
-
-
Heathcote, E.J.1
Marcellin, P.2
Buti, M.3
Gane, E.4
De Man, R.A.5
Krastev, Z.6
-
4
-
-
21244455293
-
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B
-
DOI 10.1056/NEJMoa042957
-
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005;352:2673-2681. (Pubitemid 41007822)
-
(2005)
New England Journal of Medicine
, vol.352
, Issue.26
, pp. 2673-2681
-
-
Hadziyannis, S.J.1
Tassopoulos, N.C.2
Jenny, H.E.3
Chang, T.-T.4
Kitis, G.5
Rizzetto, M.6
Marcellin, P.7
Seng, G.L.8
Goodman, Z.9
Ma, J.10
Arterburn, S.11
Xiong, S.12
Currie, G.13
Brosgart, C.L.14
-
5
-
-
0033983646
-
Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine
-
DOI 10.1016/S0168-8278(00)80076-8
-
Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000;32:300-306. (Pubitemid 30093910)
-
(2000)
Journal of Hepatology
, vol.32
, Issue.2
, pp. 300-306
-
-
Santantonio, T.1
Mazzola, M.2
Iacovazzi, T.3
Miglietta, A.4
Guastadisegni, A.5
Pastore, G.6
-
6
-
-
58149316191
-
Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy
-
Shouval D, Lai CL, Chang TT, Cheinquer H, Martin P, Carosi G, et al. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009;50:289-295.
-
(2009)
J Hepatol
, vol.50
, pp. 289-295
-
-
Shouval, D.1
Lai, C.L.2
Chang, T.T.3
Cheinquer, H.4
Martin, P.5
Carosi, G.6
-
7
-
-
58149296156
-
EASL clinical practice guidelines: Management of chronic hepatitis B
-
European Association For The Study Of The Liver
-
European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-242.
-
(2009)
J Hepatol
, vol.50
, pp. 227-242
-
-
-
8
-
-
51049107683
-
Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update
-
Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008;2:263-283.
-
(2008)
Hepatol Int
, vol.2
, pp. 263-283
-
-
Liaw, Y.F.1
Leung, N.2
Kao, J.H.3
Piratvisuth, T.4
Gane, E.5
Han, K.H.6
-
9
-
-
70349240414
-
Chronic hepatitis B: Update 2009
-
Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
-
(2009)
Hepatology
, vol.50
, pp. 661-662
-
-
Lok, A.S.1
McMahon, B.J.2
-
10
-
-
40849105240
-
Hepatitis B: Reflections on the current approach to antiviral therapy
-
Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008;48:S2-19.
-
(2008)
J Hepatol
, vol.48
-
-
Zoulim, F.1
Perrillo, R.2
-
11
-
-
34247538953
-
Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
-
DOI 10.1136/gut.2005.089722
-
Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007;56:699-705. (Pubitemid 46662938)
-
(2007)
Gut
, vol.56
, Issue.5
, pp. 699-705
-
-
Bonino, F.1
Marcellin, P.2
Lau, G.K.K.3
Hadziyannis, S.4
Jin, R.5
Piratvisuth, T.6
Germanidis, G.7
Yurdaydin, C.8
Diago, M.9
Gurel, S.10
Lai, M.-Y.11
Brunetto, M.R.12
Farci, P.13
Popescu, M.14
McCloud, P.15
-
12
-
-
65449117946
-
Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B
-
Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009;49:1141-1150.
-
(2009)
Hepatology
, vol.49
, pp. 1141-1150
-
-
Brunetto, M.R.1
Moriconi, F.2
Bonino, F.3
Lau, G.K.4
Farci, P.5
Yurdaydin, C.6
-
13
-
-
35948931362
-
A pilot study of extended duration peginterferon Alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B
-
DOI 10.1111/j.1572-0241.2007.01449.x
-
Gish RG, Lau DT, Schmid P, Perrillo R. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B. Am J Gastroenterol 2007;102:2718-2723. (Pubitemid 350179320)
-
(2007)
American Journal of Gastroenterology
, vol.102
, Issue.12
, pp. 2718-2723
-
-
Gish, R.G.1
Lau, D.T.-Y.2
Schmid, P.3
Perrillo, R.4
-
14
-
-
65449123444
-
Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients
-
Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151-1157.
-
(2009)
Hepatology
, vol.49
, pp. 1151-1157
-
-
Moucari, R.1
Mackiewicz, V.2
Lada, O.3
Ripault, M.P.4
Castelnau, C.5
Martinot-Peignoux, M.6
-
15
-
-
77955703978
-
Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels
-
Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010;52:454-461.
-
(2010)
Hepatology
, vol.52
, pp. 454-461
-
-
Rijckborst, V.1
Hansen, B.E.2
Cakaloglu, Y.3
Ferenci, P.4
Tabak, F.5
Akdogan, M.6
-
16
-
-
4544239807
-
Peginterferon Alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B
-
DOI 10.1056/NEJMoa040431
-
Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-1217. (Pubitemid 39296307)
-
(2004)
New England Journal of Medicine
, vol.351
, Issue.12
, pp. 1206-1217
-
-
Marcellin, P.1
Lau, G.K.K.2
Bonino, F.3
Farci, P.4
Hadziyannis, S.5
Jin, R.6
Lu, Z.-M.7
Piratvisuth, T.8
Germanidis, G.9
Yurdaydin, C.10
Diago, M.11
Gurel, S.12
Lai, M.-Y.13
Button, P.14
Pluck, N.15
-
17
-
-
77958091146
-
Extended (2 years) treatment with peginterferon alfa-2a [40kD] improves sustained response rates in genotype D patients with HBeAg negative chronic hepatitis B
-
Lampertico P, Vigano M, Di Costanzo G, Sagnelli E, Fasano M, Di Marco V, et al. Extended (2 years) treatment with peginterferon alfa-2a [40kD] improves sustained response rates in genotype D patients with HBeAg negative chronic hepatitis B. J Hepatol 2010;52:S45.
-
(2010)
J Hepatol
, vol.52
-
-
Lampertico, P.1
Vigano, M.2
Di Costanzo, G.3
Sagnelli, E.4
Fasano, M.5
Di Marco, V.6
-
18
-
-
77955383602
-
A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B
-
Rijckborst V, Ter Borg MJ, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, et al. A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am J Gastroenterol 2010;105:1762-1769.
-
(2010)
Am J Gastroenterol
, vol.105
, pp. 1762-1769
-
-
Rijckborst, V.1
Ter Borg, M.J.2
Cakaloglu, Y.3
Ferenci, P.4
Tabak, F.5
Akdogan, M.6
-
19
-
-
66449121130
-
Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a
-
Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009;136 (2169-2179):e2161-2164.
-
(2009)
Gastroenterology
, vol.136
, Issue.2169-2179
-
-
Marcellin, P.1
Bonino, F.2
Lau, G.K.3
Farci, P.4
Yurdaydin, C.5
Piratvisuth, T.6
-
20
-
-
77955984417
-
Pros and cons of peginterferon versus nucleos (t)ide analogues for treatment of chronic hepatitis B
-
Sonneveld MJ, Janssen HL. Pros and cons of peginterferon versus nucleos (t)ide analogues for treatment of chronic hepatitis B. Curr Hepat Rep 2010;9:91-98.
-
(2010)
Curr Hepat Rep
, vol.9
, pp. 91-98
-
-
Sonneveld, M.J.1
Janssen, H.L.2
-
21
-
-
73449089431
-
Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a
-
Moucari R, Martinot-Peignoux M, Mackiewicz V, Boyer N, Ripault MP, Castelnau C, et al. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a. Antivir Ther 2009;14:1183-1188.
-
(2009)
Antivir Ther
, vol.14
, pp. 1183-1188
-
-
Moucari, R.1
Martinot-Peignoux, M.2
Mackiewicz, V.3
Boyer, N.4
Ripault, M.P.5
Castelnau, C.6
-
22
-
-
0037381649
-
Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy
-
DOI 10.1053/jhep.2003.50148
-
Lampertico P, Del Ninno E, Vigano M, Romeo R, Donato MF, Sablon E, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003;37:756-763. (Pubitemid 36397385)
-
(2003)
Hepatology
, vol.37
, Issue.4
, pp. 756-763
-
-
Lampertico, P.1
Del, N.E.2
Vigano, M.3
Romeo, R.4
Donato, M.F.5
Sablon, E.6
Morabito, A.7
Colombo, M.8
-
23
-
-
0034802538
-
Hepatitis B e antigen-negative chronic hepatitis B
-
DOI 10.1053/jhep.2001.27834
-
Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001;34:617-624. (Pubitemid 32927983)
-
(2001)
Hepatology
, vol.34
, Issue.4 I
, pp. 617-624
-
-
Hadziyannis, S.J.1
Vassilopoulos, D.2
-
24
-
-
34548311958
-
Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis
-
DOI 10.1002/hep.21723
-
Buster EH, Hansen BE, Buti M, Delwaide J, Niederau C, Michielsen PP, et al. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology 2007;46:388-394. (Pubitemid 47344773)
-
(2007)
Hepatology
, vol.46
, Issue.2
, pp. 388-394
-
-
Buster, E.H.C.J.1
Hansen, B.E.2
Buti, M.3
Delwaide, J.4
Niederau, C.5
Michielsen, P.P.6
Flisiak, R.7
Zondervan, P.E.8
Schalm, S.W.9
Janssen, H.L.A.10
|